Physician profile
Michael J Sassmann
NPI 1295049914
$2,443.79
in general payments reported to CMS, 2019-2025
23 companies · $24.51 in 2025
The $24.51 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $852 · 2023: $514 · 2024: $559 · 2025: $24.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $264.91 | 2021-2024 | |
| Grifols USA, LLC | $264.49 | 2021-2023 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $243.75 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $243.31 | 2021-2024 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $224.76 | 2021-2024 | |
| Novo Nordisk INC | $160.59 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $146.39 | 2021-2023 | Jardiance, Mounjaro |
| Abbvie INC. | $115.13 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.19 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $93.64 | 2022-2023 | Eliquis |
| Amgen INC. | $84.71 | 2023-2024 | Repatha, Otezla, Prolia |
| Mylan Specialty L.P. | $81.20 | 2021-2024 | Yupelri |
| Astellas Pharma US INC | $78.49 | 2023-2024 | Veozah |
| Recordati_rare_diseases_inc. | $58.98 | 2023-2024 | Signifor Lar, Isturisa |
| Collegium Pharmaceutical, INC. | $47.69 | 2023-2024 | Xtampza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $42.09 | 2022 | |
| Janssen Pharmaceuticals, INC | $41.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $40.90 | 2023 | Belsomra |
| Amarin Pharma, INC. | $33.00 | 2021 | |
| Genentech USA, INC. | $23.53 | 2024 | Xolair |
| Acadia Pharmaceuticals INC | $22.10 | 2021 | |
| Digestive Care, INC. | $18.36 | 2024 | Pertzye |
| Biohaven Pharmaceuticals, INC. | $17.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sassmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.